* 中国生物科技公司--礼邦医药9637.HK周五早盘升2.8%。
* 该公司此前公告称，预计上半年期内亏损同比收窄15-25%至1.58-1.78亿元人民币，主要由于就AP306与R1 Therapeutics订立的许可及股权协议项下确认的许可收入及美信罗销售增长带动收入增加；若干股份的赎回责任已于上市前终止（属一次性因素），报告期内不再计提相关利息，令亏损收窄。
* 恒⽣⽣物科技指数.HSBIO盘中一度升2%。（完）
更多股市简讯请点选CN-CMN-HOT
* 中国生物科技公司--礼邦医药9637.HK周五早盘升2.8%。
* 该公司此前公告称，预计上半年期内亏损同比收窄15-25%至1.58-1.78亿元人民币，主要由于就AP306与R1 Therapeutics订立的许可及股权协议项下确认的许可收入及美信罗销售增长带动收入增加；若干股份的赎回责任已于上市前终止（属一次性因素），报告期内不再计提相关利息，令亏损收窄。
* 恒⽣⽣物科技指数.HSBIO盘中一度升2%。（完）
更多股市简讯请点选CN-CMN-HOT
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.